Table 2.

Overview on clinical studies using the NS5B inhibitor sofosbovir

Study	Patient population	Therapy	Duration (wk)	SVR	Comments
ION-1	First-line therapy	SOF + LDV	12	99%
		SOF + LDV + R	12	97%
		SOF + LDV	24	98%
		SOF + LDV + R	24	99%
ION-2	Re-therapy	SOF + LDV	12	94%	86% cirrhotic
		SOF + LDV + R	12	96%	82% cirrhotic
		SOF + LDV	24	99%	100% cirrhotic
		SOF + LDV + R	24	99%	86% cirrhotic
ION-3	First-line therapy	SOF + LDV	8	94%	Only non-cirrhotic
		SOF + LDV + R	8	93%	Only non-cirrhotic
		SOF + LDV	12	95%	Only non-cirrhotic

SOF: Sofosbuvir; LDV: Ledipasvir; R: Ribavirin; SVR: Sustained virological response.